Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amniotic membrane extract eye drops (66dabf)
- Development stage
- Unknown
- Lead developer
- Hospital Nacional Profesor Alejandro Posadas
- Administration
- Ophthalmic
01
Overview
Amniotic membrane extract eye drops (AMEED) is a biologic therapy developed by the Hospital Nacional Profesor Alejandro Posadas in Argentina for the treatment of hyposecretory dry eye syndrome. The drug is produced by processing and re-hydrating amniotic membranes to create a topical solution rich in growth factors and cytokines. These components work to promote corneal healing and reduce ocular surface inflammation. AMEED is currently being evaluated in a Phase 3 clinical trial (NCT05598242) as a potential alternative to autologous serum eye drops for patients with severe ocular surface pathologies.
- Other names
- amniotic membrane extract
Beyond the preview
Go deeper on amniotic membrane extract eye drops (66dabf).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amniotic membrane extract eye drops (66dabf).